Study of belumosudil for cGVHD in diverse patients withdrawn
Disease control
Terminated
This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander people aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. Participants would take …
Phase: PHASE2 • Sponsor: Kadmon, a Sanofi Company • Aim: Disease control
Last updated May 02, 2026 21:21 UTC